Lisa Panitz
Family · Lutherville, MDNPI 1336517077
Payments from drug & device makers
Across 274 payments — averaging $18.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$821
- AbbVie$717
- Lilly USA, LLC$602
- AstraZeneca$472
- Sumitomo Pharma America, Inc.$419
- Pfizer$321
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,156100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 46 | $821 |
| AbbVie | 36 | $717 |
| Lilly USA, LLC | 38 | $602 |
| AstraZeneca | 26 | $472 |
| Sumitomo Pharma America, Inc. | 19 | $419 |
| Pfizer | 19 | $321 |
| Exact Sciences | 9 | $206 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $176 |
| GSK | 9 | $160 |
| Amarin Pharma, Inc. | 6 | $131 |
| Amgen(2 entities) | 6 | $125 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $112 |
| Sunovion Pharmaceuticals Inc. | 5 | $92 |
| Phathom Pharmaceuticals, Inc. | 5 | $92 |
| Bausch Health US, LLC | 4 | $78 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $77 |
| Otsuka America Pharmaceutical, Inc. | 3 | $76 |
| Johnson & Johnson | 2 | $66 |
| Urovant Sciences Inc | 3 | $62 |
| Idorsia Pharmaceuticals US Inc | 2 | $39 |
| Astellas Pharma US Inc | 2 | $37 |
| Abbott | 2 | $26 |
| Madrigal Pharmaceuticals | 1 | $25 |
| Redhill Biopharma Inc. | 1 | $23 |
| GRT US Holding, Inc. | 1 | $21 |
| Watermark Medical, Inc. | 1 | $20 |
| Almatica Pharma LLC | 1 | $20 |
| Corium, LLC | 1 | $20 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Dynavax Technologies Corporation | 1 | $18 |
| Novartis | 1 | $18 |
| Nevro Corp. | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
How this compares
$5,156 in reported general payments places this provider in the 90th percentile of 2,843 family providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 59 | $86,466 |
| MounjaroTirzepatide | 31 | $39,080 |
| EliquisApixaban | 40 | $38,497 |
| FarxigaDapagliflozin Propanediol | 28 | $29,666 |
| TrulicityDulaglutide | 19 | $21,681 |
| RybelsusSemaglutide | 12 | $18,744 |
| XareltoRivaroxaban | 15 | $15,595 |
| MyrbetriqMirabegron | 13 | $13,778 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $11,850 |
| GemtesaVibegron | 12 | $9,388 |
| Rosuvastatin Calcium | 187 | $4,425 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $3,313 |
| Atorvastatin Calcium | 232 | $2,577 |
| Levothyroxine Sodium | 171 | $2,456 |
| SynthroidLevothyroxine Sodium | 34 | $2,365 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $821 | $105,21071 claims |
| Lilly USA, LLCMounjaro, Trulicity | $602 | $60,76250 claims |
| PfizerEliquis | $321 | $38,49740 claims |
| AstraZenecaFarxiga | $472 | $29,66628 claims |
| Johnson & JohnsonXarelto | $66 | $15,59515 claims |
| Astellas Pharma US IncMyrbetriq | $37 | $13,77813 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $419 | $9,38812 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $19 | $2,456171 claims |
| AbbVieSynthroid | $717 | $2,36534 claims |
| Almatica Pharma LLCSertraline Hcl | $20 | $1,43859 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,843 family providers in Maryland.
Other family in Lutherville
- Ariana ChaoLutherville$727K
- Erika HoffmanPotomac$226K
- Caroline MansySalisbury$106K
- Hazel Jones-ParkerBaltimore$96K
- Brittany WilsonBaltimore$88K
- Meredith SagalHunt Valley$82K
- Sharon Dudley-BrownBel Air$67K
- Joy MaulikSalisbury$47K
- Kristin AttiogbeChevy Chase$42K
- Sametta SanyaoluFulton$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.